270 Days of Continuous Glucose Monitoring.
One Injection. No Surgery.
Current CGM devices require sensor replacement every 7–14 days, costing up to $7,000 annually. Lumee™ Glucose delivers clinical-grade monitoring for 270+ days from a single hypodermic needle injection — making CGM genuinely accessible across the entire diabetes spectrum.
From "Can You Afford It?"
to "Do You Need It?"
Current CGM technology has proven clinical benefit — but cost and sensor longevity limit adoption to only the most intensively managed patients. Lumee™ Glucose removes both barriers simultaneously.
Source: Dexcom, Medtronic, Abbott, and Senseonics public product pages. Profusa cost projection based on internal modeling at >80% gross margin.
Human Clinical Data That Speaks for Itself
The Lumee™ Glucose CGM has been validated in a multi-center clinical trial spanning Europe and Asia.
A CGM Market Ready for Disruption
See the full EU revenue roadmap, financial projections, and funding runway.
View Financial Overview→Request clinical data, ask about EU availability, or schedule a product demonstration.
Request Clinical Info →